Cantel Medical Appoints New Director

Business Wire, Oct 31, 2007

LITTLE FALLS, N.J. -- CANTEL MEDICAL CORP. (NYSE:CMN) Announced the appointment of Mark N. Diker to fill the vacancy created by the resignation of Dr. Spencer Foreman as a director on June 25, 2007. Mr. Diker is co-founder of Diker Management LLC, a registered investment adviser which focuses on healthcare and other industries, where he has served as co-managing partner since February 2003. From 2000 to 2002, he served as a General Partner at Arsenal Capital Partners, a private equity firm he co-founded. He received his BA from Harvard College and his MBA from Harvard Business School, where he graduated as a Baker Scholar. Mr. Diker is the son of Charles M. Diker, Chairman of our Board of Directors.

R. Scott Jones, Cantel's President & CEO commented, "We expect Mark's relevant market experience and talents to enhance the make-up of Cantel's Board of Directors. We welcome his participation as we enter the next phase of our growth and development."

Cantel Medical Corp. is a leading provider of infection prevention and control products in the healthcare market. Our products include specialized medical device reprocessing systems for renal dialysis and endoscopy, dialysate concentrates and other dialysis supplies, disposable infection control products primarily for the dental industry, water purification equipment, sterilants, disinfectants and cleaners, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens.

For further information, visit the Cantel Web site at www.cantelmedical.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.